What Trump’s Latest Moves Mean for the Industry
May 27, 2025
Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.
6 min read
Business Practice
Partnerships To Be Precise
By Elizabeth Hickman, Dave Miller
April 11, 2025
In the ever volatile, highly regulated precision medicine development sector, the agility and expertise of a CDMO can make or break a commercial drug candidate.
3 min read
Trump Speech Suggests Pharma Tariffs Incoming
By Stephanie Vine
April 9, 2025
US President threatens “major tariff” on pharmaceuticals.
2 min read
The Trump Effect on Cell and Gene: Science versus Shockwaves
April 1, 2025
Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.
9 min read
The Future of the NIH
By Hernan Bazan
March 27, 2025
Thoughts on the US National Institutes of Health and its role in funding research for non-opioid therapeutics.
2 min read
Building a Resilient CGT Workforce
By Daniel Palmacci
March 26, 2025
With competition for skilled employees in cell and gene therapy manufacturing high, companies need to ensure they are investing in training and mentorship.
3 min read
Calling Out Misleading Information
By Rob Coker
March 24, 2025
FDA letter sent to Edenbridge Pharmaceuticals demonstrates the challenges of getting pharma advertising right.
2 min read
Resilient Supply Chains in an Uncertain World; View From a CDMO
March 10, 2025
From geopolitical conflicts to cyber threats, CDMOs must rethink resilience.
3 min read
Biden’s Legacy; Trump’s Agenda: Part 2
March 7, 2025
In part 2 of our roundtable discussion, thought leaders discuss what Trump could do for drug pricing and whether change is to be feared or embraced.
7 min read
Biden’s Legacy; Trump’s Agenda: Part 1
March 5, 2025
Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma? Experts share their thoughts in a roundtable discussion.
10 min read